Selank Evidence Guide
Selank is the most practical entry point for research into anxiolytic peptides with any human evidence. It has Russian regulatory approval, an RCT in anxiety/cognitive impairment, and a benign side effect profile with no dependence or sedation. The limitations are real - all evidence is from Russian sources, no Western validation exists, and the intranasal half-life is under 5 minutes. But within its approved application (anxiety-driven cognitive impairment), it is the best-evidenced option in its class in this library.
Our Take
Selank is the most practical entry point for research into anxiolytic peptides with any human evidence. It has Russian regulatory approval, an RCT in anxiety/cognitive impairment, and a benign side effect profile with no dependence or sedation. The limitations are real - all evidence is from Russian sources, no Western validation exists, and the intranasal half-life is under 5 minutes. But within its approved application (anxiety-driven cognitive impairment), it is the best-evidenced option in its class in this library.
- Best for
- Anxiety reduction, cognition under stress, beginners exploring nootropic peptides
- Evidence grade
- Level C
- Confidence
- Moderate
- Starting point
- 250mcg intranasal, twice daily
Benefits and Evidence
- Anxiety Reduction: Level C, includes human evidence - Russian clinical studies report anxiolytic effects comparable to benzodiazepines without sedation or dependence. Approved for anxiety in Russia.
- Cognitive Enhancement: Level C, includes human evidence - Seredenin et al. (2002, Bull Exp Biol Med) reported improved memory and attention in 62 patients with generalized anxiety (300 mcg/day intranasal, 14 days). Uchakina et al. (2001, Int Immunopharmacol) demonstrated Selank-induced BDNF upregulation in rat hippocampus.
- Immune Modulation: Level C, includes human evidence - Evidence of immune-balancing effects including modulation of cytokine profiles and enhanced natural killer cell activity.
Side Effects and Warnings
- Generally well-tolerated
- Mild fatigue in some users
- Possible nasal irritation (intranasal)
- Rare allergic reactions
- Most clinical data from Russian research only
- Not FDA-approved or evaluated
- Limited independent replication of results
- Quality control varies between sources
Research Dosage References
- <strong>Intranasal spray</strong> - 250-500 mcg - 2-3 times daily - Most common administration route. Each spray typically delivers 250 mcg. Russian clinical formulation.
- <strong>Subcutaneous injection</strong> - 250-500 mcg - Once or twice daily - Alternative to intranasal. Used in research settings.
Mechanism of Action
Selank modulates brain chemistry through multiple pathways: 1. BDNF upregulation: Increases brain-derived neurotrophic factor expression, supporting neuroplasticity and memory. 2. Serotonin modulation: Influences serotonin metabolism and transport, contributing to anxiolytic effects. 3. GABA modulation: Enhances GABAergic transmission without benzodiazepine-like sedation or dependence. 4. Enkephalin stabilization: Inhibits degradation of enkephalins, endogenous opioid peptides involved in mood regulation. 5. Immune modulation: Retains tuftsin-like immunomodulatory properties, balancing immune function. 6. Gene expression: Modulates expression of over 50 genes related to inflammation, immune function, and neuroplasticity.
Legal Status
Approved for clinical use in Russia as a nasal spray. Not FDA-approved in the US or EU. Available as a research peptide in Western countries. Not a controlled substance. Classified as a nootropic in online research chemical markets.
Primary Sources
- Selank: a new generation of anxiolytics. Vestn Ross Akad Med Nauk, 2008.
- Anxiolytic-like and nootropic effects of Selank. Behav Brain Res, 2010.